# Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

> **NCT00163540** · PHASE4 · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Encephalitis, Tick-borne

## Interventions

- **BIOLOGICAL:** Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

## Key facts

- **NCT ID:** NCT00163540
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** — (—)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163540, "Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00163540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*